Rituxirel 100 mg Injection Supplier USA | Pharmaceutical Exporter from India

Rituxirel 100 mg Injection: High-Quality Rituximab Biosimilar for Global Oncology Care

Are you searching for a dependable Rituxirel 100 mg injection exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced biologics. We provide a regulatory-compliant, cold-chain-integrated supply chain serving the USA, UK, Australia, and South Africa, ensuring that critical immunotherapy treatments reach healthcare institutions with pharmaceutical-grade integrity and efficient global logistics.

Detailed Product Overview: What is Rituxirel 100 mg?

Rituxirel 100 mg Injection is a therapeutic monoclonal antibody containing the active ingredient Rituximab. Manufactured by Reliance Life Sciences, Rituxirel is a high-quality biosimilar designed to provide the same clinical efficacy and safety profile as the reference product Rituxan.

For international B2B procurement, Rituxirel 100 mg offers a cost-effective solution for targeted therapy against CD20-positive B-cell malignancies and various autoimmune conditions. It is supplied as a 100 mg/10 ml single-dose vial concentrate for intravenous infusion.

Primary Therapeutic Indications

Rituxirel 100 mg is globally utilized for the following:

1. Non-Hodgkin Lymphoma (NHL): Specifically for Follicular Lymphoma and Diffuse Large B-Cell Lymphoma (DLBCL).

2. Chronic Lymphocytic Leukemia (CLL): In combination with chemotherapy for previously untreated and treated patients.

3. Rheumatoid Arthritis (RA): For adult patients who have had an inadequate response to other treatments.

4. Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA): Managing severe vascular inflammation.

5. Pemphigus Vulgaris: A rare autoimmune disease causing skin and mucous membrane blisters.

Mechanism of Action: Targeted B-Cell Depletion

Rituxirel works through a sophisticated immunological process:

• CD20 Binding: The antibody specifically targets the CD20 antigen found on the surface of pre-B and mature B-lymphocytes.

• Immune Cytotoxicity: Once bound, it initiates cell lysis (destruction) via:

  • Complement-Dependent Cytotoxicity (CDC)

  • Antibody-Dependent Cellular Cytotoxicity (ADCC)

• Selective Targeting: It spares hematopoietic stem cells, allowing the body to regenerate healthy B-cells after the course of therapy.

Administration and Clinical Safety

• Infusion Method: Must be administered as an intravenous (IV) infusion by qualified medical staff. It is not to be given as an IV bolus or push.

• Pre-medication: Patients usually receive acetaminophen and an antihistamine to prevent infusion-related reactions.

• Cold-Chain Storage: Requires strict storage at 2°C to 8°C (36°F to 46°F). Protect from light and do not shake or freeze.

• Key Monitoring: Infusion Reactions: Monitoring is essential during the first hour of the first infusion.

• Hepatitis B Reactivation: Screening is mandatory before treatment initiation.

• CBC Monitoring: Regular blood counts are required during therapy.

Why Source Rituxirel from Ernest Oncology?

• Authentic Indian Exporter: Direct access to genuine Reliance Life Sciences inventory, ensuring 100% product authenticity and competitive wholesale pricing.

• Specialized Cold-Chain Export: We use validated thermal packaging and real-time monitoring to ensure Rituximab remains within the required temperature range during transit to the USA, UK, Australia, and South Africa.

• Global Compliance: We provide full B2B documentation, including GMP compliance, batch-specific COAs, and necessary export permits.

• Bulk Supply Stability: We specialize in fulfilling large-scale orders for hospital groups, hematology centers, and regional distributors.